Article info
PDFClinical and epidemiological research
Extended report
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
- Correspondence to Dr Primal Kaur, Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; pkaur{at}amgen.com
Citation
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
Publication history
- Received November 17, 2015
- Revised June 28, 2016
- Accepted June 29, 2016
- First published July 27, 2016.
Online issue publication
February 17, 2017
Article Versions
- Previous version (27 July 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/